Moulton J S, Moore P T, Mencini R A
Department of Radiology, St. Anthony Hospital, Denver, CO 80204.
AJR Am J Roentgenol. 1989 Nov;153(5):941-5. doi: 10.2214/ajr.153.5.941.
Surgical thoracostomy tube placement and radiologically guided catheter drainage are standard therapy for loculated pleural fluid collections. Treatment may fail if the catheter is not placed optimally within the loculation or if the fluid is hemorrhagic or fibrinous. We studied the value of transcatheter urokinase instillation in facilitating drainage of hemorrhagic or fibrinous nonhemorrhagic loculated pleural collections in 11 patients with 13 loculated pleural collections. Eight of the fluid collections were hemorrhagic, five were nonhemorrhagic. Five patients had had a thoracostomy tube placed surgically and all had had radiologically guided placement of single lumen drainage catheters managed with suction, saline irrigation, and mechanical guidewire manipulation. This therapy had failed to drain the loculations completely over an average of 10 days (range, 1-22 days). Urokinase (1000 units/ml) was instilled into the drainage catheters in 80- to 150-ml aliquots. After 1-2 hr, suction was reinstituted and the procedure was repeated. Twelve (92%) of the 13 collections were drained completely after an average of 4.3 instillations (range, three to eight instillations). Successful urokinase therapy required an average of 28 hr (range, 8-75 hr). In one case, therapy was discontinued after partial resolution for unrelated clinical reasons. There were no complications. These results suggest that transcatheter intracavitary urokinase therapy is a safe and effective method to facilitate drainage of loculated hemorrhagic or fibrinous nonhemorrhagic pleural fluid collections.
外科胸腔闭式引流管置入术和放射引导下导管引流是局限性胸腔积液的标准治疗方法。如果导管未最佳地置于局限性积液内,或者积液为血性或纤维蛋白性,则治疗可能失败。我们研究了经导管注入尿激酶在促进11例患者13处局限性胸腔积液(其中8处积液为血性,5处为非血性)引流中的价值。5例患者曾接受外科胸腔闭式引流管置入术,所有患者均接受了放射引导下单腔引流导管的置入,并采用吸引、盐水冲洗和机械导丝操作进行处理。这种治疗方法在平均10天(范围1 - 22天)内未能完全引流局限性积液。将尿激酶(1000单位/毫升)以80至150毫升的等分剂量注入引流导管。1 - 2小时后,重新开始吸引并重复该操作。13处积液中有12处(92%)在平均4.3次注入(范围3至8次注入)后完全引流。成功的尿激酶治疗平均需要28小时(范围8至75小时)。在1例中,因无关的临床原因在部分缓解后停止治疗。无并发症发生。这些结果表明,经导管腔内尿激酶治疗是促进局限性血性或纤维蛋白性非血性胸腔积液引流的一种安全有效的方法。